{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-25-023207","form_type":"8-K","ticker":"VYCO","cik":"0001424768","company_name":"VYCOR MEDICAL INC","filed_at":"2025-11-14T23:59:59+00:00","discovered_at":"2026-05-14T18:02:39.379988+00:00","generated_at":"2026-05-16T19:49:47.693634+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Vycor Medical Q3 revenue $514K (+31% YoY); posts GAAP operating profit of $32K","bullets":["Q3 2025 revenue $513,792, up 31% YoY; Vycor Medical division up 32% to $492K, mostly US growth.","GAAP operating profit of $32,085 in Q3 vs. loss in prior year; non-GAAP operating profit $60,162.","Nine-month revenue $1,446,523 (+28% YoY); non-GAAP operating profit $166,262 vs. $27,021 in 2024.","Gross margin dipped to 88% (Q3) and 84% (9-month) from 90% due to validation costs and international mix.","Three new peer-reviewed papers on VBAS published; NeuroEyeCoach study validates home-based therapy."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-25-023207","json":"https://secwatch.observer/filing/0001493152-25-023207.json","markdown":"https://secwatch.observer/filing/0001493152-25-023207.md","text":"https://secwatch.observer/filing/0001493152-25-023207.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1424768/000149315225023207/0001493152-25-023207-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1424768/000149315225023207/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T19:49:47.693634+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}